Biocan Novel DHPPI/L4 10 doses

Biocan Novel DHPPI/L4 10 doses

Biocan Novel DHPPI/L4 10 doses


*THIS PRODUCT IS TRANSPORTED IN THE COOLING SECTION OF THE TRANSPORT COMPANY'S AIRCRAFT*


Canine live vaccine against parvovirosis, distemper, inf. hepatitis, inf. laryngotracheitis and parainfluenza and inactivated liquid vaccine against four serovars of leptospirosis


Composition per 1 ml dose

Lyophilisate (live attenuated):

Canine Distemper virus, strain CDV Bio 11/A - min. 103.1 TCID50*, max. 105.1 TCID50*

Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50**, max. 105.3 TCID50*

Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - min. 104.3 TCID50*, min. 106.6 TCID50*

Canine Parainfluenza Type 2virus, strain CPiV-2 Bio 15 - min. 103.1 TCID50*, max. 105.1 TCID50*

Solvent (inactivated):

Leptospira interrogans serogroup Icterohaemorrhagiae, serovar icterohaemorrhagiae, strain MSLB 1089     GMT** ≥ 1:51 ALR***

Leptospira interrogans serogroup canicola,  serovar canicola, strain MSLB 1090            GMT** ≥ 1:51 ALR***

Leptospira kirschneri serogroup grippotyphosa, serovar grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 ALR***

Leptospira interrogans serogroup australis, serovar bratislava, strain MSLB 1088 GMT** ≥ 1:51 ALR***

Adjuvant: aluminium hydroxide (quantified as Al2O3)  1.8-2.2 mg

* Tissue culture infectious dose – 50%

** Geometric mean titre

*** Antibody micro agglutination-lytic reaction

Indications

Active immunization of dogs from 6 weeks of age.

  • to prevent mortality and clinical signs caused by canine distemper virus

  • to prevent mortality and clinical signs caused by canine adenovirus type 1

  • to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2

  • to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus

  • to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus

  • to prevent clinical signs, infection and urinary excretion caused by L.interrogans serogroup Australis serovar Bratislava

  • to prevent clinical signs and urinary excretion and reduce infection caused by L.interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterhaemorrhagiae serovar Icterohaemorrhagiae

  • to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa

Onset of immunity:

- 3 weeks after the first vaccination for CDV, CAV, CPV,

- 3 weeks after completion of the primary course for CPiV and

- 4 weeks after completion of the primary course for Leptospira components.

Duration of immunity:

At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. At least one year following the primary vaccination course for canine parainfluenza virus and  Leptospira components.

The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

Contraindications

Do not use in case of hypersensitivity to the active substance, to the adjuvant or to any of the excipients..

Adverse reactions

Following subcutaneous administration in dogs, a small transient swelling (up to 5 cm) may commonly be observed at the injection site, these can occasionally be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.

In rare cases gastrointestinal signs such as diarrhoea and vomiting or anorexia and decreased activity are possible.

As with any vaccine rare, occasional hypersensitivity reactions may occur. If such a reaction occurs, appropriate treatment should be administered without delay.

If you notice any serious or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

The frequency of adverse reactions is defined using the following convention

Very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)common (more than 1 but less than 10 animals in 100 animals)uncommon (more than 1 but less than 10 animals in 1,000 animals)rare (more than 1 but less than 10 animals in 10,000 animals)very rare (less than 1 animal in 10,000 animals, including isolated reports)

Target species

Dogs.

Dosage for each species, route(s) and method of administration

Subcutaneous use.

Dose and route of administration:

Aseptically reconstitute the lyophilisate with the solvent. Shake well and administer immediately the entire content (1 ml) of the reconstituted product.

Reconstituted vaccine: pinkish or yellowish colour with slight opalescence.

Primary vaccination scheme:

Two doses of Biocan Novel DHPPi/L4 3-4 weeks apart from 6 weeks of age.

Rabies:

If protection against Rabies is required:

First dose: Biocan Novel DHPPi/L4 from 8–9 weeks of age.

Second dose: Biocan Novel DHPPi/L4R 3–4 weeks later, but not before 12 weeks of age.

The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. However, in field studies, 10 % of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3–

Write a review

Note: HTML is not translated!
    Bad           Good

  • Product Code: Biocan Novel DHPPI/L4 10 doses
  • Availability: In Stock
  • €120.10